This preview shows page 1. Sign up to view the full content.
Unformatted text preview: allenges in identifying and quantifying
environmental exposures, technological
obstacles to generating sufficient and useful
genotypic information, and the difficulties
of studying humans. Yet this problem can be
solved. Vigorous development of crosscutting genomic tools to catalyse advances
in understanding the genetics of common
disease and in pharmacogenomics is needed.
Prominent among these will be a detailed
haplotype map of the human genome
(see Grand Challenge I-3) that can be used
for whole-genome association studies of
all diseases in all populations, as well as
further advances in sequencing and
genotyping technology to make such studies
feasible (see ‘Quantum leaps’, below).
More efficient strategies for detecting
rare alleles involved in common disease
are also needed, as the hypothesis that alleles
that increase risk for common diseases are
themselves common30 will probably not be
universally true. Computational and experimental methods to detect gene–gene
and gene–environment interactions, as well
as methods allowing interfacing of a variety
of relevant databases, are also required
(Box 3). By obtaining unbiased assessments
of the relative disease risk that particular
gene variants contribute...
View Full Document
This document was uploaded on 04/02/2014.
- Fall '14
- The Tempest